{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:22:19Z","timestamp":1790349739431,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001661","name":"Universit\u00e4t Heidelberg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jval.2023.06.020","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T21:13:11Z","timestamp":1690492391000},"page":"1590-1600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology"],"prefix":"10.1016","volume":"26","author":[{"given":"Daniel Tobias","family":"Michaeli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Michaeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jval.2023.06.020_bib1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.amjmed.2009.04.012","article-title":"Medical bankruptcy in the United States, 2007: results of a national study","volume":"122","author":"Himmelstein","year":"2009","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.jval.2023.06.020_bib2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/jamaoncol.2015.0373","article-title":"Five years of cancer drug approvals: innovation, efficacy, and costs","volume":"1","author":"Mailankody","year":"2015","journal-title":"JAMA Oncol"},{"issue":"22","key":"10.1016\/j.jval.2023.06.020_bib3","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts","volume":"121","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jval.2023.06.020_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/EDBK_100028","article-title":"An arm and a leg: the rising cost of cancer drugs and impact on access","volume":"41","author":"Leighl","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jval.2023.06.020_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: new estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J\u00a0Health Econ"},{"issue":"9","key":"10.1016\/j.jval.2023.06.020_bib6","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"Estimated Research and Development investment needed to bring a new medicine to market, 2009-2018","volume":"323","author":"Wouters","year":"2020","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jval.2023.06.020_bib7","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jama.2020.0442","article-title":"Profitability of large pharmaceutical companies compared with other large public companies","volume":"323","author":"Ledley","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jval.2023.06.020_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.6875","article-title":"Comparison of sales income and Research and Development costs for FDA-approved cancer drugs sold by originator drug companies","volume":"2","author":"Tay-Teo","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.jval.2023.06.020_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.18623","article-title":"Association of Research and Development investments with treatment costs for new drugs approved from 2009 to 2018","volume":"5","author":"Wouters","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.jval.2023.06.020_bib10","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S1470-2045(20)30139-X","article-title":"Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis","volume":"21","author":"Vokinger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2023.06.020_bib11","doi-asserted-by":"crossref","first-page":"o2163","DOI":"10.1136\/bmj.o2163","article-title":"Inflation Reduction Act and US drug pricing","volume":"378","author":"Sarpatwari","year":"2022","journal-title":"BMJ"},{"issue":"35","key":"10.1016\/j.jval.2023.06.020_bib13","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.22.00535","article-title":"Overall survival, progression-free survival, and tumor response benefit supporting initial US Food and Drug Administration approval and indication extension of new cancer drugs, 2003-2021","volume":"40","author":"Michaeli","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2023.06.020_bib14","doi-asserted-by":"crossref","first-page":"h4679","DOI":"10.1136\/bmj.h4679","article-title":"Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review","volume":"351","author":"Wang","year":"2015","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jval.2023.06.020_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.13224","article-title":"Characteristics of clinical studies used for US Food and Drug Administration supplemental indication approvals of drugs and biologics, 2017 to 2019","volume":"4","author":"Dhodapkar","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.jval.2023.06.020_bib16","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s10637-022-01227-5","article-title":"Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA","volume":"40","author":"Michaeli","year":"2022","journal-title":"Invest New Drugs"},{"issue":"5","key":"10.1016\/j.jval.2023.06.020_bib17","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40258-022-00737-w","article-title":"Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland","volume":"20","author":"Michaeli","year":"2022","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.jval.2023.06.020_bib64","article-title":"Therapeutic value of first versus supplemental indications of drugs in US and Europe (2011-20): retrospective cohort study","volume":"382","author":"Vokinger","year":"2023","journal-title":"BMJ"},{"issue":"16","key":"10.1016\/j.jval.2023.06.020_bib18","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/jama.2014.13235","article-title":"Indication-specific pricing for cancer drugs","volume":"312","author":"Bach","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2023.06.020_bib19","article-title":"Feasibility and attractiveness of indication value-based pricing in key EU countries","volume":"4","author":"Flume","year":"2016","journal-title":"J\u00a0Mark Access Health Policy"},{"issue":"1","key":"10.1016\/j.jval.2023.06.020_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40258-019-00517-z","article-title":"Price models for multi-indication drugs: a systematic review","volume":"18","author":"Campillo-Artero","year":"2020","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"10.1016\/j.jval.2023.06.020_bib21","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jval.2021.11.1376","article-title":"The role of indication-based pricing in future pricing and reimbursement policies: a systematic review","volume":"25","author":"Preckler","year":"2022","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2023.06.020_bib22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2217\/cer-2017-0018","article-title":"Indication-specific pricing of pharmaceuticals in the US healthcare system","volume":"6","author":"Pearson","year":"2017","journal-title":"J\u00a0Comp Eff Res"},{"issue":"2","key":"10.1016\/j.jval.2023.06.020_bib23","doi-asserted-by":"crossref","first-page":"pky016","DOI":"10.1093\/jncics\/pky016","article-title":"Affordability and price increases of new cancer drugs in clinical guidelines, 2007-2016","volume":"2","author":"Hwang","year":"2018","journal-title":"JNCI Cancer Spectr"},{"issue":"7","key":"10.1016\/j.jval.2023.06.020_bib24","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S1470-2045(17)30415-1","article-title":"Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks","volume":"18","author":"Del Paggio","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jval.2023.06.020_bib25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1257\/jep.29.1.139","article-title":"Pricing in the market for anticancer drugs","volume":"29","author":"Howard","year":"2015","journal-title":"J\u00a0Econ Perspect"},{"issue":"10","key":"10.1016\/j.jval.2023.06.020_bib26","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.6004\/jnccn.2020.7574","article-title":"The association between clinical value and financial cost of cancer treatments: a cross-sectional analysis","volume":"18","author":"Mitchell","year":"2020","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.jval.2023.06.020_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2020.113042","article-title":"Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US","volume":"258","author":"Salas-Vega","year":"2020","journal-title":"Soc Sci Med"},{"issue":"4","key":"10.1016\/j.jval.2023.06.020_bib28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/1758834016644465","article-title":"Pricing of innovative drugs: correlation between incremental cost and survival gain in four countries","volume":"8","author":"Mengato","year":"2016","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.jval.2023.06.020_bib29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/JCO.2016.72.2124","article-title":"Trajectories of injectable cancer drug costs after launch in the United States","volume":"36","author":"Gordon","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.jval.2023.06.020_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.2026","article-title":"Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy implications in the US and Europe","volume":"7","author":"Vokinger","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.jval.2023.06.020_bib31","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jamaoncol.2016.4275","article-title":"The rising price of cancer drugs-A new old problem?","volume":"3","author":"Prasad","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.jval.2023.06.020_bib32","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1001\/jamaoncol.2016.0648","article-title":"Drug pricing trends for orally administered anticancer medications reimbursed by commercial health plans, 2000-2014","volume":"2","author":"Dusetzina","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jval.2023.06.020_bib33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12962-020-00223-x","article-title":"Establishing a reasonable price for an orphan drug","volume":"18","author":"Berdud","year":"2020","journal-title":"Cost Eff Resour Alloc"},{"issue":"6","key":"10.1016\/j.jval.2023.06.020_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-007199","article-title":"Effectiveness, safety and costs of orphan drugs: an evidence-based review","volume":"5","author":"Onakpoya","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.jval.2023.06.020_bib35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1172-6-42","article-title":"Pricing and reimbursement of orphan drugs: the need for more transparency","volume":"6","author":"Simoens","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.jval.2023.06.020_bib36","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1186\/s13063-018-2877-z","article-title":"The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: rationale and design of the database and the collection of evidence available at approval of novel drugs","volume":"19","author":"Ladanie","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.jval.2023.06.020_bib37","doi-asserted-by":"crossref","first-page":"k2815","DOI":"10.1136\/bmj.k2815","article-title":"How to use FDA drug approval documents for evidence syntheses","volume":"362","author":"Ladanie","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2023.06.020_bib39","author":"Drugs@FDA"},{"issue":"6","key":"10.1016\/j.jval.2023.06.020_bib43","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMhpr0807774","article-title":"Limits on Medicare\u2019s ability to control rising spending on cancer drugs","volume":"360","author":"Bach","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"9596","key":"10.1016\/j.jval.2023.06.020_bib44","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.jval.2023.06.020_bib45","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1200\/JCO.2017.77.1592","article-title":"Efficacy, safety, and regulatory approval of Food and Drug Administration-designated breakthrough and nonbreakthrough cancer medicines","volume":"36","author":"Hwang","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.jval.2023.06.020_bib46","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jamainternmed.2013.11813","article-title":"Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US Food and Drug Administration: the class of 2008","volume":"174","author":"Moore","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.jval.2023.06.020_bib47","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jama.2013.7900","article-title":"The Food and Drug Administration Amendments Act and postmarketing commitments","volume":"310","author":"Fain","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.jval.2023.06.020_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057744","article-title":"Time to inclusion in clinical guidance documents for non-oncological orphan drugs and biologics with expedited FDA designations: a retrospective survival analysis","volume":"11","author":"Rodriguez","year":"2021","journal-title":"BMJ Open"},{"issue":"12","key":"10.1016\/j.jval.2023.06.020_bib49","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.3937","article-title":"Medicare spending on drugs with accelerated approval, 2015-2019","volume":"2","author":"Rome","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"12","key":"10.1016\/j.jval.2023.06.020_bib50","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/jamainternmed.2021.5989","article-title":"Estimated Medicare spending on cancer drug indications with a confirmed lack of clinical benefit after US Food and Drug Administration accelerated approval","volume":"181","author":"Shahzad","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"16","key":"10.1016\/j.jval.2023.06.020_bib51","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1001\/jama.2022.5403","article-title":"Drug pricing with evidence development","volume":"327","author":"Robinson","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2023.06.020_bib52","author":"Pitts"},{"key":"10.1016\/j.jval.2023.06.020_bib53","series-title":"Malignant: How Bad Policy and Bad Evidence Harm People With Cancer","author":"Prasad","year":"2020"},{"key":"10.1016\/j.jval.2023.06.020_bib54","article-title":"FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis","volume":"381","author":"Michaeli","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2023.06.020_bib55","author":"Michaeli"},{"issue":"10","key":"10.1016\/j.jval.2023.06.020_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140002","article-title":"Access to orphan drugs: A comprehensive review of legislations, regulations and policies in 35 countries","volume":"10","author":"Gammie","year":"2015","journal-title":"PLoS One"},{"issue":"13-14","key":"10.1016\/j.jval.2023.06.020_bib57","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.drudis.2012.02.005","article-title":"Orphan drug development: an economically viable strategy for biopharma R&D","volume":"17","author":"Meekings","year":"2012","journal-title":"Drug Discov Today"},{"issue":"2","key":"10.1016\/j.jval.2023.06.020_bib58","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s43441-021-00364-y","article-title":"Valuation and returns of drug development companies: lessons for bioentrepreneurs and investors","volume":"56","author":"Michaeli","year":"2022","journal-title":"Ther Innov Regul Sci"},{"issue":"8","key":"10.1016\/j.jval.2023.06.020_bib59","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s10198-021-01427-5","article-title":"Value drivers of development stage biopharma companies","volume":"23","author":"Michaeli","year":"2022","journal-title":"Eur J Health Econ"},{"issue":"6","key":"10.1016\/j.jval.2023.06.020_bib60","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0167-6296(97)00004-0","article-title":"Understanding DALYs (disability-adjusted life years)","volume":"16","author":"Murray","year":"1997","journal-title":"J\u00a0Health Econ"},{"issue":"11","key":"10.1016\/j.jval.2023.06.020_bib61","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jval.2019.07.007","article-title":"Unmet medical need: an introduction to definitions and stakeholder perceptions","volume":"22","author":"Vreman","year":"2019","journal-title":"Value Health"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301523030656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301523030656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:32:45Z","timestamp":1761096765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301523030656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1098301523030656"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2023.06.020","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2023.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}